ArticlemedRxiv : the preprint server for health sciences2026
Posttraumatic Stress Disorder Epigenome-Wide Association Studies in the Million Veteran Program.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Genomic studies have improved our understanding of posttraumatic stress disorder (PTSD) biology. Epigenetic differences in DNA methylation can reflect environmental influences, which are critical in PTSD etiology, and may additionally differentiate between PTSD cases and controls or distinguish severity of PTSD symptoms. We conducted PTSD epigenome-wide association studies (EWAS) in a large cohort, n = 22,141 subjects from the United States V.A. Million Veteran Program (MVP), with the PTSD Checklist (PCL-17), including 17,674 European ancestry (EUR), 3,430 African ancestry (AFR), and 1,037 admixed American descent (AMR). We evaluated the 17-item PCL-Total as well as symptom subdomains (re-experiencing, avoidance, and hyperarousal), and used lasso regression on electronic health records to define lifetime PTSD diagnoses. There were 9,413 total cases of Lifetime PTSD and 27,257 controls, with 5,184 cases and 19,382 controls in EUR, 3,095 cases and 6,240 controls in AFR, and 1,134 cases and 1,635 controls in AMR. We identified a total of 241 epigenome-wide-significant associated CpG sites across all PTSD traits. We replicated 5 out of 11 CpG sites reported in a prior (Psychiatric Genomics Consortium) PTSD EWAS. Overlap with differentially methylated CpG sites in subregions of the amygdala and hippocampus of human postmortem brains of individuals with PTSD vs. controls was evaluated at the CpG and gene levels. Ten genes of the 195 identified in the brain study overlapped with the 192 identified in our EWAS. There was significant enrichment of genes downregulated in somatostatin interneurons and brain endothelial cells. Regression analyses showed that PTSD case status was significantly associated with accelerated DNA methylation aging. Contrary to previous PTSD EWAS findings, smoking status stratification suggested that the association between PTSD and methylation of the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.